A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration

Trial Profile

A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Sevacizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors Jiangsu T-mab BioPharma
  • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 27 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.
    • 15 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top